Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Imatinib in Metastatic Melanoma
NCT00402662Phase 2Terminated
- Sponsor
- Yale University
- Start
- Feb 2006
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus and imatinib in melanoma, sponsored by Yale University. Primary endpoint: Objective Response Rate. Started Feb 2006; status: terminated.
02
Drugs
everolimusimatinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00402662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00402662.